Literature DB >> 21121066

Improved myocardial perfusion and cardiac function by controlled-release basic fibroblast growth factor using fibrin glue in a canine infarct model.

Shao-ping Nie1, Xiao Wang, Shi-bin Qiao, Qiu-tang Zeng, Ju-quan Jiang, Xiao-qing Liu, Xiang-ming Zhu, Guo-xiang Cao, Chang-sheng Ma.   

Abstract

OBJECTIVE: Angiogenic therapy is emerging as a potential strategy for the treatment of ischemic heart disease but is limited by a relatively short half-life of growth factors. Fibrin glue (FG) provides a reservoir for controlled-release of growth factors. The aim of this study was to evaluate the effects of basic fibroblast growth factor (bFGF) incorporating FG on angiogenesis and cardiac performance in a canine infarct model.
METHODS: Acute myocardial infarction was induced by ligation of the left anterior descending coronary artery (LAD). Group I (n=6) underwent ligation of LAD alone. In Group II, transmural channels were created in the infarct area (n=6). In Group III, non-transmural channels were created to locate FG cylinders containing bFGF (n=6). Eight weeks after operation, myocardial perfusion was assessed by single photon emission computed tomography, cardiac function by echocardiography, and vascular development by immunohistochemical staining.
RESULTS: Total vascular density and the number of large vessels (internal diameter ≥50 μm) were dramatically higher in Group III than in Groups I and II at eight weeks. Only the controlled-release group exhibited an improvement in regional myocardial perfusion associated with lower defect score. Animals in Group III presented improved cardiac regional systolic and diastolic functions as well as global systolic function in comparison with the other two groups.
CONCLUSIONS: Enhanced and sustained angiogenic response can be achieved by controlled-release bFGF incorporating FG within transmyocardial laser channels, thus enabling improvement in myocardial perfusion and cardiac function.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 21121066      PMCID: PMC2997396          DOI: 10.1631/jzus.B1000302

Source DB:  PubMed          Journal:  J Zhejiang Univ Sci B        ISSN: 1673-1581            Impact factor:   3.066


  36 in total

Review 1.  The use of fibrin glue in skin grafts and tissue-engineered skin replacements: a review.

Authors:  L J Currie; J R Sharpe; R Martin
Journal:  Plast Reconstr Surg       Date:  2001-11       Impact factor: 4.730

Review 2.  Delivery strategies to achieve therapeutic myocardial angiogenesis.

Authors:  R Kornowski; S Fuchs; M B Leon; S E Epstein
Journal:  Circulation       Date:  2000-02-01       Impact factor: 29.690

3.  Basic fibroblast growth factor in a porcine model of chronic myocardial ischemia: a comparison of angiographic, echocardiographic and coronary flow parameters.

Authors:  J J Lopez; E R Edelman; A Stamler; M G Hibberd; P Prasad; R P Caputo; J P Carrozza; P S Douglas; F W Sellke; M Simons
Journal:  J Pharmacol Exp Ther       Date:  1997-07       Impact factor: 4.030

Review 4.  Angiogenesis for the treatment of vascular diseases.

Authors:  P S Chawla; M H Keelan; N Kipshidze
Journal:  Int Angiol       Date:  1999-09       Impact factor: 2.789

5.  Regional wall motion index for infarct and noninfarct regions after reperfusion in acute myocardial infarction: comparison with global wall motion index.

Authors:  P D Bourdillon; T M Broderick; S G Sawada; W F Armstrong; T Ryan; J C Dillon; N S Fineberg; H Feigenbaum
Journal:  J Am Soc Echocardiogr       Date:  1989 Nov-Dec       Impact factor: 5.251

6.  Effects of intramyocardial administration of slow-release basic fibroblast growth factor on angiogenesis and ventricular remodeling in a rat infarct model.

Authors:  Zhan-Qiang Shao; Kentaro Takaji; Yukihiro Katayama; Ryuji Kunitomo; Hisashi Sakaguchi; Zhong-Fang Lai; Michio Kawasuji
Journal:  Circ J       Date:  2006-04       Impact factor: 2.993

7.  FGF-2 binding to fibrin(ogen) is required for augmented angiogenesis.

Authors:  Abha Sahni; Alok A Khorana; Raymond B Baggs; Hu Peng; Charles W Francis
Journal:  Blood       Date:  2005-09-13       Impact factor: 22.113

8.  The VIVA trial: Vascular endothelial growth factor in Ischemia for Vascular Angiogenesis.

Authors:  Timothy D Henry; Brian H Annex; George R McKendall; Michael A Azrin; John J Lopez; Frank J Giordano; P K Shah; James T Willerson; Raymond L Benza; Daniel S Berman; C Michael Gibson; Alex Bajamonde; Amy Chen Rundle; Jennifer Fine; Edward R McCluskey
Journal:  Circulation       Date:  2003-03-18       Impact factor: 29.690

9.  Heparin-fibroblast growth factor-fibrin complex: in vitro and in vivo applications to collagen-based materials.

Authors:  C DeBlois; M F Côté; C J Doillon
Journal:  Biomaterials       Date:  1994-07       Impact factor: 12.479

10.  Non-angiogenic FGF-2 protects the ischemic heart from injury, in the presence or absence of reperfusion.

Authors:  Zhi-Sheng Jiang; Wattamon Srisakuldee; Fabienne Soulet; Gerard Bouche; Elissavet Kardami
Journal:  Cardiovasc Res       Date:  2004-04-01       Impact factor: 10.787

View more
  9 in total

Review 1.  Cardiac fibrosis: potential therapeutic targets.

Authors:  Shuin Park; Ngoc B Nguyen; Arash Pezhouman; Reza Ardehali
Journal:  Transl Res       Date:  2019-03-09       Impact factor: 7.012

2.  Automatic high-resolution infarct detection using volumetric multiphase dual-energy CT.

Authors:  Veit Sandfort; Alan C Kwan; Comfort Elumogo; Davis M Vigneault; Rolf Symons; Amir Pourmorteza; Kelly Rice; Cynthia Davies-Venn; Mark A Ahlman; Chia-Ying Liu; Stefan L Zimmerman; David A Bluemke
Journal:  J Cardiovasc Comput Tomogr       Date:  2017-04-18

3.  Optimized energy of spectral CT for infarct imaging: Experimental validation with human validation.

Authors:  Veit Sandfort; Srikanth Palanisamy; Rolf Symons; Amir Pourmorteza; Mark A Ahlman; Kelly Rice; Tom Thomas; Cynthia Davies-Venn; Bernhard Krauss; Alan Kwan; Ankur Pandey; Stefan L Zimmerman; David A Bluemke
Journal:  J Cardiovasc Comput Tomogr       Date:  2017-02-11

4.  A therapeutic angiogenesis of sustained release of basic fibroblast growth factor using biodegradable gelatin hydrogel sheets in a canine chronic myocardial infarction model.

Authors:  Motoyuki Kumagai; Kenji Minakata; Hidetoshi Masumoto; Masaya Yamamoto; Atsushi Yonezawa; Takafumi Ikeda; Kyokun Uehara; Kazuhiro Yamazaki; Tadashi Ikeda; Kazuo Matsubara; Masayuki Yokode; Akira Shimizu; Yasuhiko Tabata; Ryuzo Sakata; Kenji Minatoya
Journal:  Heart Vessels       Date:  2018-05-14       Impact factor: 2.037

5.  Use of decellularized scaffolds combined with hyaluronic acid and basic fibroblast growth factor for skin tissue engineering.

Authors:  Zhengzheng Wu; Lina Fan; Bin Xu; Yongliang Lin; Peng Zhang; Xing Wei
Journal:  Tissue Eng Part A       Date:  2014-10-14       Impact factor: 3.845

Review 6.  A deep dive into the darning effects of biomaterials in infarct myocardium: current advances and future perspectives.

Authors:  Thiagarajan Hemalatha; Mayilvahanan Aarthy; Suryalakshmi Pandurangan; Numbi Ramudu Kamini; Niraikulam Ayyadurai
Journal:  Heart Fail Rev       Date:  2021-08-03       Impact factor: 4.654

Review 7.  Current Trends in Biomaterial Utilization for Cardiopulmonary System Regeneration.

Authors:  Adegbenro Omotuyi John Fakoya; David Adeiza Otohinoyi; Joshua Yusuf
Journal:  Stem Cells Int       Date:  2018-04-29       Impact factor: 5.443

8.  Intramyocardial delivery of bFGF with a biodegradable and thermosensitive hydrogel improves angiogenesis and cardio-protection in infarcted myocardium.

Authors:  Hongling Zhu; Xiaoyan Li; Mingjie Yuan; Weiguo Wan; Miaoyang Hu; Xiaoding Wang; Xuejun Jiang
Journal:  Exp Ther Med       Date:  2017-08-24       Impact factor: 2.447

9.  Recent advances and challenges on application of tissue engineering for treatment of congenital heart disease.

Authors:  Antonia Mantakaki; Adegbenro Omotuyi John Fakoya; Fatemeh Sharifpanah
Journal:  PeerJ       Date:  2018-10-25       Impact factor: 2.984

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.